Unilever considering IPO of ice cream business in the US - Bloomberg
Unilever Plc (NYSE:UL) is evaluating an initial public offering of its ice cream business in the U.S. The company is also ...
Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.
US Pork Giant Smithfield Foods Raises $522M After Pricing IPO Below Range
Smithfield Foods and its Chinese parent raised around $522 million from the U.S. pork giant's initial public offering after ...
Cement Producer Titan America Seeks up to $3.3 Billion Valuation in US IPO
(Reuters) - Titan America is seeking a valuation of up to $3.32 billion in its New York initial public offering, the ...
Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO
Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...
Northpointe Bancshares Begins $201 Million IPO Effort
Northpointe Bancshares plans $201.25M IPO for retail banking, residential lending, and digital deposit banking. Explore more ...
J&J-Backed Medtech Firm HistoSonics Considers US IPO
HistoSonics Inc., a medical device company whose backers include Johnson & Johnson’s venture capital arm, is weighing a US ...
Smithfield Foods Prices IPO Below Range in US Market Comeback
The IPO valued the pork producer at $7.95 billion, ahead of a market debut that will see the company return to a U.S.
Karman Holdings Aims High With $100 Million US IPO Plan
Learn about Karman Holdings' upcoming $100 million US IPO, their focus on missile and space systems, and the financial ...
Upstream2d
What Venture Global’s IPO means for its founders' net worth — and for the company
Analysts say outlook is good after uneven trading start; leaders Sabel and Pender see windfall from stock listing ...
Ascentage Pharma’s US Shares Climb After $126 Million IPO
Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s ...
Biocon Biologics plans IPO for biosimilars business by Mar 2026: CEO
The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public ...